| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T157 |
0-96 |
Sentence |
denotes |
• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT |
| T158 |
97-142 |
Sentence |
denotes |
• 18 to 75 years of age with severe infection |
| T159 |
143-192 |
Sentence |
denotes |
• Primary outcome of time to clinical improvement |
| T160 |
193-230 |
Sentence |
denotes |
• N = 20 ruxolitinib + standard care |
| T161 |
231-295 |
Sentence |
denotes |
• N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily |
| T162 |
296-400 |
Sentence |
denotes |
• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335) |
| T163 |
401-457 |
Sentence |
denotes |
• Improvement in lung computerized tomography (CT) scans |
| T164 |
458-627 |
Sentence |
denotes |
• Significantly reduced cytokine levels and CRP by day 3 • Ruxolitinib may hasten time of chest CT scan improvement and mitigate systemic inflammation (Cao et al., 2020) |
